Jason Luke, MD, FACP, University of Pittsburgh, Pittsburgh, PA, shares his highlights in melanoma from AACR 2023. The Phase II KEYNOTE-942 (NCT03897881) clinical trial explored adjuvant treatment with the personalized cancer vaccine mRNA-4157 and pembrolizumab in participants with high-risk melanoma, demonstrating a reduced the likelihood of melanoma recurring or causing death by 44% when compared to pembrolizumab alone. The Phase I/II trial MK-3475-02C/KEYMAKER-U02 (NCT04303169) investigated neoadjuvant vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with stage IIIB-D melanoma, showing numerically higher objective response, event-free survival (EFS), and recurrence-free survival (RFS) rates. Both Phase II studies are now launching into Phase III, holding the potential to eventually impact standard of care. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть